Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by XTX Topco Ltd

XTX Topco Ltd lessened its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 46.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,197 shares of the company’s stock after selling 10,775 shares during the period. XTX Topco Ltd’s holdings in Viridian Therapeutics were worth $164,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Viridian Therapeutics by 2.7% in the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 59,281 shares of the company’s stock valued at $799,000 after purchasing an additional 1,570 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Viridian Therapeutics by 34.7% in the 1st quarter. Victory Capital Management Inc. now owns 552,850 shares of the company’s stock valued at $7,452,000 after purchasing an additional 142,410 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of Viridian Therapeutics by 579.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 362,893 shares of the company’s stock valued at $4,892,000 after purchasing an additional 309,518 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Viridian Therapeutics by 0.8% in the 1st quarter. Bank of New York Mellon Corp now owns 198,177 shares of the company’s stock valued at $2,671,000 after purchasing an additional 1,655 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of Viridian Therapeutics by 17.0% in the 1st quarter. Principal Financial Group Inc. now owns 208,836 shares of the company’s stock valued at $2,815,000 after purchasing an additional 30,392 shares during the last quarter.

Viridian Therapeutics Price Performance

VRDN stock opened at $18.85 on Thursday. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.54 billion, a PE ratio of -4.92 and a beta of 0.42. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The business’s fifty day moving average price is $16.17 and its 200 day moving average price is $15.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.00). The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. Viridian Therapeutics’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.81) EPS. On average, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on VRDN shares. JMP Securities decreased their price target on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC decreased their price target on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Oppenheimer boosted their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. The Goldman Sachs Group boosted their price objective on Viridian Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Finally, Royal Bank Of Canada cut their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.00.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.